{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:38:22Z","timestamp":1794746302102,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["431232613"],"award-info":[{"award-number":["431232613"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["392923329"],"award-info":[{"award-number":["392923329"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["431232613"],"award-info":[{"award-number":["431232613"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["450557679"],"award-info":[{"award-number":["450557679"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Federal Ministry of Education and Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nanobodies are emerging as attractive biopharmaceuticals due to their small size, stability and target specificity. However, their therapeutic use has largely been restricted to extracellular targets because of a lack of efficient delivery methods. This limitation is particularly relevant for diseases caused by dysfunctional intracellular proteins, such as cystic fibrosis. Here we show that cell-permeable nanobodies can modulate an intracellular disease-relevant target: the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel carrying the common F508del mutation. By combining a CFTR-binding nanobody with cell-penetrating peptides, we achieved intracellular delivery in cystic fibrosis bronchial epithelial cells. The delivered nanobody stabilizes misfolded F508del-CFTR, promotes its maturation and trafficking to the apical membrane and restores chloride channel activity. Moreover, the cell-permeable nanobody enhances the efficacy of approved CFTR modulator drug combination in primary airway epithelial cultures from patients with cystic fibrosis. These findings establish cell-permeable nanobodies as promising biopharmaceuticals for intracellular protein targeting and therapeutic modulation.<\/jats:p>","DOI":"10.1038\/s41589-026-02199-w","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:03:00Z","timestamp":1776416580000},"page":"1155-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A cell-permeable nanobody to restore F508del cystic fibrosis transmembrane conductance regulator activity"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2806-6536","authenticated-orcid":false,"given":"Luise","family":"Franz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihomir","family":"Rubil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7490-9946","authenticated-orcid":false,"given":"Marie","family":"Overtus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Kemnitz-Hassanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-3262","authenticated-orcid":false,"given":"Cedric","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7457-4742","authenticated-orcid":false,"given":"Christian P. R.","family":"Hackenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","volume":"40","author":"G Walsh","year":"2022","unstructured":"Walsh, G. & Walsh, E. Biopharmaceutical benchmarks 2022. Nat. Biotechnol. 40, 1722\u20131760 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"885672","DOI":"10.3389\/fimmu.2022.885672","volume":"13","author":"R Mosch","year":"2022","unstructured":"Mosch, R. & Guchelaar, H. J. Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients. Front. Immunol. 13, 885672 (2022).","journal-title":"Front. Immunol."},{"key":"2199_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"2199_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","volume":"77","author":"MM Harmsen","year":"2007","unstructured":"Harmsen, M. M. & De Haard, H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13\u201322 (2007).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"2199_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0167-4838(99)00030-8","volume":"1431","author":"RH van der Linden","year":"1999","unstructured":"van der Linden, R. H. et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta 1431, 37\u201346 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"2199_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jovcevska","year":"2020","unstructured":"Jovcevska, I. & Muyldermans, S. The therapeutic potential of nanobodies. BioDrugs 34, 11\u201326 (2020).","journal-title":"BioDrugs"},{"key":"2199_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2021.09.005","volume":"176","author":"TR Wagner","year":"2021","unstructured":"Wagner, T. R. & Rothbauer, U. Nanobodies\u2014little helpers unravelling intracellular signaling. Free Radic. Biol. Med. 176, 46\u201361 (2021).","journal-title":"Free Radic. Biol. Med."},{"key":"2199_CR8","doi-asserted-by":"publisher","first-page":"15307","DOI":"10.1074\/jbc.REV120.012960","volume":"295","author":"RW Cheloha","year":"2020","unstructured":"Cheloha, R. W., Harmand, T. J., Wijne, C., Schwartz, T. U. & Ploegh, H. L. Exploring cellular biochemistry with nanobodies. J. Biol. Chem. 295, 15307\u201315327 (2020).","journal-title":"J. Biol. Chem."},{"key":"2199_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.853008","volume":"13","author":"C Ishiwatari-Ogata","year":"2022","unstructured":"Ishiwatari-Ogata, C. et al. Ozoralizumab, a humanized anti-TNF\u03b1 NANOBODY\u00ae compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of administration of an anti-TNF\u03b1 IgG. Front. Immunol. 13, 853008 (2022).","journal-title":"Front. Immunol."},{"key":"2199_CR10","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1039\/C8SC02910E","volume":"9","author":"A Klein","year":"2018","unstructured":"Klein, A. et al. Live-cell labeling of endogenous proteins with nanometer precision by transduced nanobodies. Chem. Sci. 9, 7835\u20137842 (2018).","journal-title":"Chem. Sci."},{"key":"2199_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14772","volume":"8","author":"EA Katrukha","year":"2017","unstructured":"Katrukha, E. A. et al. Probing cytoskeletal modulation of passive and active intracellular dynamics using nanobody-functionalized quantum dots. Nat. Commun. 8, 14772 (2017).","journal-title":"Nat. Commun."},{"key":"2199_CR12","doi-asserted-by":"publisher","first-page":"e20378","DOI":"10.7554\/eLife.20378","volume":"5","author":"KW Teng","year":"2016","unstructured":"Teng, K. W. et al. Labeling proteins inside living cells using external fluorophores for microscopy. Elife 5, e20378 (2016).","journal-title":"Elife"},{"key":"2199_CR13","first-page":"33","volume":"59","author":"T Hebbrecht","year":"2020","unstructured":"Hebbrecht, T. et al. Nanobody click chemistry for convenient site-specific fluorescent labelling, single step immunocytochemistry and delivery into living cells by photoporation and live cell imaging. Nat. Biotechnol. 59, 33\u201343 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2199_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015227","volume":"5","author":"A Blanco-Toribio","year":"2010","unstructured":"Blanco-Toribio, A., Muyldermans, S., Frankel, G. & Fern\u00e1ndez, L. \u00c1 Direct injection of functional single-domain antibodies from e. coli into human cells. PLoS ONE 5, e15227 (2010).","journal-title":"PLoS ONE"},{"key":"2199_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1083\/jcb.201502074","volume":"211","author":"SJ Ittig","year":"2015","unstructured":"Ittig, S. J. et al. A bacterial type III secretion-based protein delivery tool for broad applications in cell biology. J. Cell Biol. 211, 913\u2013931 (2015).","journal-title":"J. Cell Biol."},{"key":"2199_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/pro.2926","volume":"25","author":"VJ Bruce","year":"2016","unstructured":"Bruce, V. J., Lopez-Islas, M. & McNaughton, B. R. Resurfaced cell-penetrating nanobodies: a potentially general scaffold for intracellularly targeted protein discovery. Protein Sci. 25, 1129\u20131137 (2016).","journal-title":"Protein Sci."},{"key":"2199_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nchem.2811","volume":"9","author":"HD Herce","year":"2017","unstructured":"Herce, H. D. et al. Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells. Nat. Chem. 9, 762\u2013771 (2017).","journal-title":"Nat. Chem."},{"key":"2199_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37237-x","volume":"14","author":"X Sun","year":"2023","unstructured":"Sun, X., Zhou, C., Xia, S. & Chen, X. Small molecule-nanobody conjugate induced proximity controls intracellular processes and modulates endogenous unligandable targets. Nat. Commun. 14, 1635 (2023).","journal-title":"Nat. Commun."},{"key":"2199_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41557-021-00661-x","volume":"13","author":"AFL Schneider","year":"2021","unstructured":"Schneider, A. F. L., Kithil, M., Cardoso, M. C., Lehmann, M. & Hackenberger, C. P. R. Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives. Nat. Chem. 13, 530\u2013539 (2021).","journal-title":"Nat. Chem."},{"key":"2199_CR20","doi-asserted-by":"publisher","first-page":"22075","DOI":"10.1002\/anie.202103068","volume":"60","author":"AFL Schneider","year":"2021","unstructured":"Schneider, A. F. L., Benz, L. S., Lehmann, M. & Hackenberger, C. P. R. Cell-permeable nanobodies allow dual-color super-resolution microscopy in untransfected living cells. Angew. Chem. Int. Ed. Engl. 60, 22075\u201322080 (2021).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2199_CR21","first-page":"24785","volume":"145","author":"H He","year":"2023","unstructured":"He, H., Zhou, C. & Chen, X. ATNC: versatile nanobody chimeras for autophagic degradation of intracellular unligandable and undruggable proteins. J. Am. Chem. Soc. 145, 24785\u201324795 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2199_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","volume":"402","author":"SY Graeber","year":"2023","unstructured":"Graeber, S. Y. & Mall, M. A. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet 402, 1185\u20131198 (2023).","journal-title":"Lancet"},{"key":"2199_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","volume":"77","author":"JR Riordan","year":"2008","unstructured":"Riordan, J. R. CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701\u2013726 (2008).","journal-title":"Annu. Rev. Biochem."},{"key":"2199_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"MA Mall","year":"2024","unstructured":"Mall, M. A. et al. Cystic fibrosis. Nat. Rev. Dis. Primers 10, 53 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2199_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445\u2212tezacaftor\u2212ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2199_CR26","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","volume":"201","author":"MA Mall","year":"2020","unstructured":"Mall, M. A., Mayer-Hamblett, N. & Rowe, S. M. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. Am. J. Respir. Crit. Care Med. 201, 1193\u20131208 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2199_CR27","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor\u2212tezacaftor\u2212ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2199_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","volume":"205","author":"SY Graeber","year":"2022","unstructured":"Graeber, S. Y. et al. Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am. J. Respir. Crit. Care Med. 205, 540\u2013549 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2199_CR29","doi-asserted-by":"crossref","unstructured":"Nichols, D. P. et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J. Clin. Invest. 133, e167957 (2023).","DOI":"10.1172\/JCI167957"},{"key":"2199_CR30","doi-asserted-by":"crossref","unstructured":"Schaupp, L. et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur. Respir. J. 62, 2202153 (2023).","DOI":"10.1183\/13993003.02153-2022"},{"key":"2199_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey, M. et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax 78, 835\u2013839 (2023).","journal-title":"Thorax"},{"key":"2199_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10714-y","volume":"10","author":"M Sigoillot","year":"2019","unstructured":"Sigoillot, M. et al. Domain-interface dynamics of CFTR revealed by stabilizing nanobodies. Nat. Commun. 10, 2636 (2019).","journal-title":"Nat. Commun."},{"key":"2199_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jmb.2014.07.026","volume":"427","author":"L He","year":"2015","unstructured":"He, L. et al. Restoration of NBD1 thermal stability is necessary and sufficient to correct \u2206F508 CFTR folding and assembly. J. Mol. Biol. 427, 106\u2013120 (2015).","journal-title":"J. Mol. Biol."},{"key":"2199_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1096\/fj.12-216119","volume":"27","author":"L He","year":"2013","unstructured":"He, L. et al. Correctors of \u0394F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 27, 536\u2013545 (2013).","journal-title":"FASEB J."},{"key":"2199_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1126\/science.ade2216","volume":"378","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk, K. & Chen, J. Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators. Science 378, 284\u2013290 (2022).","journal-title":"Science"},{"key":"2199_CR36","doi-asserted-by":"crossref","unstructured":"Veit, G. et al. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 5, e139983 (2020).","DOI":"10.1172\/jci.insight.139983"},{"key":"2199_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.chembiol.2023.05.001","volume":"30","author":"AG McKee","year":"2023","unstructured":"McKee, A. G. et al. General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants. Cell Chem. Biol. 30, 632\u2013642 (2023).","journal-title":"Cell Chem. Biol."},{"key":"2199_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/acs.bioconjchem.8b00855","volume":"30","author":"AFL Schneider","year":"2019","unstructured":"Schneider, A. F. L., Wallabregue, A. L. D., Franz, L. & Hackenberger, C. P. R. Targeted subcellular protein delivery using cleavable cyclic cell-penetrating peptides. Bioconjug. Chem. 30, 400\u2013404 (2019).","journal-title":"Bioconjug. Chem."},{"key":"2199_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jim.2006.07.019","volume":"315","author":"DP Simmons","year":"2006","unstructured":"Simmons, D. P. et al. Dimerisation strategies for shark IgNAR single domain antibody fragments. J. Immunol. Methods 315, 171\u2013184 (2006).","journal-title":"J. Immunol. Methods"},{"key":"2199_CR40","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/nprot.2013.102","volume":"8","author":"CS Theile","year":"2013","unstructured":"Theile, C. S. et al. Site-specific N-terminal labeling of proteins using sortase-mediated reactions. Nat. Protoc. 8, 1800\u20131807 (2013).","journal-title":"Nat. Protoc."},{"key":"2199_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1083\/jcb.201601004","volume":"215","author":"BL Timney","year":"2016","unstructured":"Timney, B. L. et al. Simple rules for passive diffusion through the nuclear pore complex. J. Cell Biol. 215, 57\u201376 (2016).","journal-title":"J. Cell Biol."},{"key":"2199_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000149783","volume":"22","author":"B Illek","year":"2008","unstructured":"Illek, B. et al. Cl transport in complemented CF bronchial epithelial cells correlates with CFTR mRNA expression levels. Cell. Physiol. Biochem. 22, 57\u201368 (2008).","journal-title":"Cell. Physiol. Biochem."},{"key":"2199_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00441-005-0062-7","volume":"323","author":"C Ehrhardt","year":"2006","unstructured":"Ehrhardt, C. et al. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o. Cell Tissue Res. 323, 405\u2013415 (2006).","journal-title":"Cell Tissue Res."},{"key":"2199_CR44","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1021\/acscentsci.8b00446","volume":"4","author":"RF Wissner","year":"2018","unstructured":"Wissner, R. F., Steinauer, A., Knox, S. L., Thompson, A. D. & Schepartz, A. Fluorescence correlation spectroscopy reveals efficient cytosolic delivery of protein cargo by cell-permeant miniature proteins. ACS Cent. Sci. 4, 1379\u20131393 (2018).","journal-title":"ACS Cent. Sci."},{"key":"2199_CR45","first-page":"24535","volume":"145","author":"JVV Arafiles","year":"2023","unstructured":"Arafiles, J. V. V. et al. Cell-surface-retained peptide additives for the cytosolic delivery of functional proteins. J. Am. Chem. Soc. 145, 24535\u201324548 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2199_CR46","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1248\/cpb.c16-00505","volume":"64","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi, T. & Futaki, S. Current understanding of direct translocation of arginine-rich cell-penetrating peptides and its internalization mechanisms. Chem. Pharm. Bull. (Tokyo) 64, 1431\u20131437 (2016).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"2199_CR47","doi-asserted-by":"publisher","first-page":"140604","DOI":"10.1016\/j.bbapap.2021.140604","volume":"1869","author":"GC Kim","year":"2021","unstructured":"Kim, G. C., Cheon, D. H. & Lee, Y. Challenge to overcome current limitations of cell-penetrating peptides. Biochim. Biophys. Acta Proteins Proteom. 1869, 140604 (2021).","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"2199_CR48","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/emboj.2013.171","volume":"32","author":"I Maejima","year":"2013","unstructured":"Maejima, I. et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 32, 2336\u20132347 (2013).","journal-title":"EMBO J."},{"key":"2199_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep09038","volume":"5","author":"HM Botelho","year":"2015","unstructured":"Botelho, H. M. et al. Protein traffic disorders: an effective high-throughput fluorescence microscopy pipeline for drug discovery. Sci. Rep. 5, 9038 (2015).","journal-title":"Sci. Rep."},{"key":"2199_CR50","doi-asserted-by":"publisher","first-page":"17459","DOI":"10.1021\/ja507790z","volume":"136","author":"HD Herce","year":"2014","unstructured":"Herce, H. D., Garcia, A. E. & Cardoso, M. C. Fundamental molecular mechanism for the cellular uptake of guanidinium-rich molecules. J. Am. Chem. Soc. 136, 17459\u201317467 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"2199_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nsmb.1727","volume":"17","author":"A Kirchhofer","year":"2010","unstructured":"Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol. 17, 133\u2013138 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2199_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/358761a0","volume":"358","author":"GM Denning","year":"1992","unstructured":"Denning, G. M. et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761\u2013764 (1992).","journal-title":"Nature"},{"key":"2199_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bph.13654","volume":"174","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation. Br. J. Pharmacol. 174, 70\u201381 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"2199_CR54","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/bkcs.70028","volume":"46","author":"S Yi","year":"2025","unstructured":"Yi, S., Ahn, Y. & Lee, N. K. Advances in methodologies for quantifying protein\u2013protein interactions in living cells. Bull. Korean Chem. Soc. 46, 574\u2013586 (2025).","journal-title":"Bull. Korean Chem. Soc."},{"key":"2199_CR55","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1128\/MCB.00087-14","volume":"34","author":"W Sadaie","year":"2014","unstructured":"Sadaie, W., Harada, Y., Matsuda, M. & Aoki, K. Quantitative In vivo fluorescence cross-correlation analyses highlight the importance of competitive effects in the regulation of protein\u2212protein interactions. Mol. Cell. Biol. 34, 3272\u20133290 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"2199_CR56","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jmb.2003.12.008","volume":"336","author":"N Kozer","year":"2004","unstructured":"Kozer, N. & Schreiber, G. Effect of crowding on protein\u2013protein association rates: fundamental differences between low and high mass crowding agents. J. Mol. Biol. 336, 763\u2013774 (2004).","journal-title":"J. Mol. Biol."},{"key":"2199_CR57","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/anie.201410006","volume":"54","author":"N Nischan","year":"2015","unstructured":"Nischan, N. et al. Covalent attachment of cyclic TAT peptides to GFP results in protein delivery into live cells with immediate bioavailability. Angew. Chem. Int. Ed. Engl. 54, 1950\u20131953 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2199_CR58","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106, 18825\u201318830 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2199_CR59","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA 108, 18843\u201318848 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2199_CR60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nchembio.1253","volume":"9","author":"T Okiyoneda","year":"2013","unstructured":"Okiyoneda, T. et al. Mechanism-based corrector combination restores \u0394F508-CFTR folding and function. Nat. Chem. Biol. 9, 444\u2013454 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"2199_CR61","doi-asserted-by":"crossref","unstructured":"Balazs, A. et al. The potentiator ivacaftor is essential for pharmacological restoration of F508del-CFTR function and mucociliary clearance in cystic fibrosis. JCI Insight 10, e187951 (2025).","DOI":"10.1172\/jci.insight.187951"},{"key":"2199_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2119\/molmed.2012.00343","volume":"19","author":"D Marcus","year":"2013","unstructured":"Marcus, D., Lichtenstein, M., Saada, A. & Lorberboum-Galski, H. Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells. Mol. Med. 19, 124\u2013134 (2013).","journal-title":"Mol. Med."},{"key":"2199_CR63","doi-asserted-by":"publisher","first-page":"8751","DOI":"10.1021\/acsnano.1c07648","volume":"16","author":"X Yang","year":"2022","unstructured":"Yang, X. et al. Probing the intracellular delivery of nanoparticles into hard-to-transfect cells. ACS Nano 16, 8751\u20138765 (2022).","journal-title":"ACS Nano"},{"key":"2199_CR64","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1089\/hum.2022.172","volume":"33","author":"G McLachlan","year":"2022","unstructured":"McLachlan, G. et al. Progress in respiratory gene therapy. Hum. Gene Ther. 33, 893\u2013912 (2022).","journal-title":"Hum. Gene Ther."},{"key":"2199_CR65","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1113\/JP288762","volume":"603","author":"A Balazs","year":"2025","unstructured":"Balazs, A. & Mall, M. A. Don\u2019t forget the mucus barrier in pulmonary drug delivery! J. Physiol. 603, 2471\u20132472 (2025).","journal-title":"J. Physiol."},{"key":"2199_CR66","doi-asserted-by":"crossref","unstructured":"Ratjen, F. et al. Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis. Eur. Respir. J. 65, 2401855 (2025).","DOI":"10.1183\/13993003.01855-2024"},{"key":"2199_CR67","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jcf.2015.11.010","volume":"15","author":"LB Gottschalk","year":"2016","unstructured":"Gottschalk, L. B. et al. Creation and characterization of an airway epithelial cell line for stable expression of CFTR variants. J. Cyst. Fibros. 15, 285\u2013294 (2016).","journal-title":"J. Cyst. Fibros."},{"key":"2199_CR68","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"2199_CR69","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4939-3804-9_7","volume":"1459","author":"MD Amaral","year":"2016","unstructured":"Amaral, M. D., Farinha, C. M., Matos, P. & Botelho, H. M. Investigating alternative transport of integral plasma membrane proteins from the ER to the Golgi: lessons from the cystic fibrosis transmembrane conductance regulator (CFTR). Methods Mol. Biol. 1459, 105\u2013126 (2016).","journal-title":"Methods Mol. Biol."},{"key":"2199_CR70","doi-asserted-by":"publisher","first-page":"111942","DOI":"10.1016\/j.isci.2025.111942","volume":"28","author":"HM Botelho","year":"2025","unstructured":"Botelho, H. M. et al. Global functional genomics reveals GRK5 as a cystic fibrosis therapeutic target synergistic with current modulators. iScience 28, 111942 (2025).","journal-title":"iScience"},{"key":"2199_CR71","doi-asserted-by":"publisher","first-page":"822437","DOI":"10.3389\/fimmu.2022.822437","volume":"13","author":"A Balazs","year":"2022","unstructured":"Balazs, A. et al. Age-related differences in structure and function of nasal epithelial cultures from healthy children and elderly people. Front. Immunol. 13, 822437 (2022).","journal-title":"Front. Immunol."}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02199-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:02:59Z","timestamp":1782442979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02199-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1038\/s41589-026-02199-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.26.591242","asserted-by":"object"}]},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.M. reports grants or contracts from Boehringer Ingelheim, Enterprise Therapeutics, Vertex Pharmaceuticals, the German Federal Ministry of Research, Technology and Space (BMFTR) and the German Research Foundation (DFG), with payments made to the institution; fees for consulting or participation on an advisory board from Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Pari, Splisense and Vertex Pharmaceuticals; payment or honoraria for lectures from Boehringer Ingelheim and Vertex Pharmaceuticals; travel reimbursement received for participation in advisory board meetings for Boehringer Ingelheim and Vertex Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}